tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

HOWL Stock Latest News

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Press ReleasesWerewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
17d ago
HOWL
Werewolf Therapeutics reports Q2 EPS (43c), consensus (38c)
PremiumThe Fly
Werewolf Therapeutics reports Q2 EPS (43c), consensus (38c)
1M ago
HOWL
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
PremiumPress Releases
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
1M ago
HOWL
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes
PremiumCompany Announcements
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes
3M ago
8K
HOWL
Werewolf announces initial trial results evaluating INDUKINE for lymphoma
PremiumThe Fly
Werewolf announces initial trial results evaluating INDUKINE for lymphoma
3M ago
HOWL
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
PremiumPress ReleasesWerewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
3M ago
HOWL
Werewolf Therapeutics’ Promising WTX-124 Clinical Trial Outcomes
Premium
Company Announcements
Werewolf Therapeutics’ Promising WTX-124 Clinical Trial Outcomes
4M ago
8K
HOWL
Werewolf Therapeutics presents data from ongoing Phase 1/1b trial of WTX-124
Premium
The Fly
Werewolf Therapeutics presents data from ongoing Phase 1/1b trial of WTX-124
4M ago
HOWL
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
PremiumPress Releases
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
4M ago
HOWL
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
PremiumPress Releases
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
4M ago
HOWL
Werewolf Therapeutics sees cash runway through at least 1Q26
PremiumThe Fly
Werewolf Therapeutics sees cash runway through at least 1Q26
5M ago
HOWL
Werewolf Therapeutics reports Q1 EPS (39c), consensus (35c)
PremiumThe Fly
Werewolf Therapeutics reports Q1 EPS (39c), consensus (35c)
5M ago
HOWL
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
PremiumPress ReleasesWerewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
5M ago
HOWL
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Premium
Press Releases
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
5M ago
HOWL
Werewolf Therapeutics presents preclinical data on IL-10 INDUKINE molecules
Premium
The Fly
Werewolf Therapeutics presents preclinical data on IL-10 INDUKINE molecules
5M ago
HOWL
Werewolf Therapeutics to present data from studies of WTX-518, WTX-712 at AACR
PremiumThe Fly
Werewolf Therapeutics to present data from studies of WTX-518, WTX-712 at AACR
6M ago
HOWL
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
PremiumPress Releases
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
6M ago
HOWL
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PremiumPress Releases
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
6M ago
HOWL
Werewolf Therapeutics initiated with an Outperform at JMP Securities
PremiumThe Fly
Werewolf Therapeutics initiated with an Outperform at JMP Securities
6M ago
HOWL
Werewolf Therapeutics Announces CSO Retirement Date
PremiumCompany AnnouncementsWerewolf Therapeutics Announces CSO Retirement Date
7M ago
8K
HOWL
Werewolf Therapeutics expects cash to fund requirements through at least 2Q25
Premium
The Fly
Werewolf Therapeutics expects cash to fund requirements through at least 2Q25
7M ago
HOWL
Werewolf Therapeutics reports Q4 EPS (33c), consensus (43c)
Premium
The Fly
Werewolf Therapeutics reports Q4 EPS (33c), consensus (43c)
7M ago
HOWL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >